Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROSEB-HC vs ALPHADERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.
Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
FDA-approved for the treatment of eczematous dermatitis, atopic dermatitis, and other glucocorticoid-responsive dermatoses complicated by fungal or bacterial infections
Hypertension,Benign prostatic hyperplasia
AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.
Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.
1.5-2 hours (terminal) after intravenous administration; prolonged in hepatic impairment.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Hydrocortisone is primarily hepatic via CYP3A4; iodoquinol is not extensively metabolized, with partial glucuronidation and enterohepatic circulation.
Hepatic via cytochrome P450 (CYP3A4); active metabolites.
Renal (primarily as metabolites; <5% unchanged); fecal (biliary excretion of metabolites).
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; less than 10% metabolized hepatically.
90-95% (albumin and corticosteroid-binding globulin).
Approximately 85% bound to albumin; minor binding to alpha-1-acid glycoprotein.
0.4-0.6 L/kg; indicates distribution into total body water and tissues.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water.
Oral: 80-90%; Intramuscular: 100%; Intravenous: 100%.
Oral bioavailability is 70-80% due to first-pass metabolism; IM bioavailability is 90-95%.
No adjustment required for topical application. Systemic absorption is minimal; however, in severe renal impairment (GFR <30 m L/min), use caution due to potential systemic corticosteroid effects.
No dose adjustment required for renal impairment.
No specific adjustment for topical use. In Child-Pugh C cirrhosis, consider the risk of systemic corticosteroid accumulation; use with caution.
No dose adjustment required for hepatic impairment.
Children >2 years: Apply a thin film to affected area twice daily for up to 7 days. Avoid prolonged use, occlusion, or application to large body surface areas. Safety in children <2 years not established.
Safety and efficacy in pediatric patients have not been established.
Elderly patients: Use the lowest effective duration and avoid prolonged use due to increased risk of skin atrophy and systemic absorption. Apply sparingly to limited areas.
No specific dose adjustment; use with caution due to potential increased skin fragility.
None
None.
Prolonged use may lead to systemic corticosteroid effects, including HPA axis suppression, Cushing's syndrome, and hyperglycemia.,Risk of secondary infection due to immunosuppression.,Local adverse reactions such as skin atrophy, striae, and perioral dermatitis.,Avoid use in diaper area or under occlusive dressings.
Orthostatic hypotension and syncope, especially with first dose,May cause dizziness, drowsiness, or lightheadedness,Use caution in patients with hepatic impairment,May exacerbate angina or heart failure
Hypersensitivity to any component (hydrocortisone, iodoquinol, or sulfites).,Viral or fungal infections without appropriate antimicrobial coverage.,Immunocompromised patients (systemic use relative).,Pregnancy (category C, use only if benefit outweighs risk).
Hypersensitivity to alpha-blockers,History of orthostatic hypotension,Micturition syncope,Severe renal impairment,Concomitant use with PDE-5 inhibitors (e.g., sildenafil) due to risk of hypotension
No clinically significant food interactions are reported for topical hydrocortisone/pramoxine. No dietary restrictions necessary.
No specific food interactions. However, high-fat meals may increase systemic absorption of topical tretinoin marginally; no dietary restrictions necessary. Avoid excessive vitamin A supplements to reduce risk of hypervitaminosis A.
FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adrenal suppression with prolonged use; avoid high doses and prolonged exposure.
Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest embryocidal and teratogenic effects at high doses. Second/third trimester: Potential for fetal harm; avoid unless benefit outweighs risk.
Present in breast milk in low concentrations. M/P ratio not determined. Use with caution, especially with high doses or prolonged treatment; risk of infant adrenal suppression theoretical.
Unknown if excreted in human milk; M/P ratio not established. Caution advised due to potential for serious adverse reactions in nursing infants.
No standard dose adjustments required for pregnancy-related pharmacokinetic changes. Use lowest effective dose for shortest duration. Avoid high-dose or prolonged use in pregnancy.
Increased plasma volume may reduce drug levels; consider dose adjustment based on therapeutic drug monitoring. No specific dose adjustment established; use lowest effective dose.
AEROSEB-HC is a combination aerosol foam containing hydrocortisone acetate 1% and pramoxine hydrochloride 1% for topical use. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly in anogenital areas. The foam formulation enhances penetration and is less messy than ointments. Advise patients to avoid contact with eyes and mucous membranes. Use with caution in patients with skin infections or atrophy. Prolonged use in intertriginous areas may increase risk of local and systemic adverse effects.
ALPHADERM (tretinoin 0.05% cream) is a retinoid used for photoaging and acne. Apply a pea-sized amount to dry skin 30 minutes after cleansing; avoid concomitant use of other topical retinoids or exfoliants to prevent irritation. Initiate therapy every other night to build tolerance. Strict sun protection required: use SPF 30+ daily. May cause initial flare of acne (retinoid 'purging') lasting 2-4 weeks. Contraindicated in pregnancy (FDA Category C).
Apply a small amount to the affected area as directed, usually 2-4 times daily.,Do not cover the area with bandages or dressings unless instructed by your doctor.,Avoid use on broken skin, open wounds, or infected areas unless specifically prescribed.,Do not use for more than 2 weeks without medical supervision, especially in the anogenital region.,If symptoms do not improve or worsen, contact your healthcare provider.,Keep away from eyes, mouth, and other mucous membranes.,Wash hands after applying unless treating hands.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Apply a thin layer to affected areas once daily at bedtime, 30 minutes after washing and drying face.,Avoid excessive sun exposure; use broad-spectrum sunscreen and protective clothing.,Do not use with other medicated topical products, including benzoyl peroxide or salicylic acid.,Expect mild redness, peeling, or stinging initially; this usually subsides with continued use.,Notify your doctor if you are pregnant, planning pregnancy, or breastfeeding.,Store at room temperature away from heat and light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROSEB-HC vs ALPHADERM, answered by our medical review team.
AEROSEB-HC is a Topical Corticosteroid that works by AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.. ALPHADERM is a Topical Corticosteroid that works by Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROSEB-HC and ALPHADERM depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROSEB-HC is: AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.. The standard adult dose of ALPHADERM is: Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROSEB-HC and ALPHADERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROSEB-HC is classified as Category C. FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adre. ALPHADERM is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest embryocidal and teratogenic effects at high doses. Second/third trimester: Potential for fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.